Spring Pharmaceutical (CYIG) 10-Q 19 Feb 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 31, 2013	Feb. 18, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CYIG	'
Entity Common Stock, Shares Outstanding	'	29,663,023
Entity Registrant Name	'China YCT International Group, Inc.	'
Entity Central Index Key	'0000847464	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (USD $)	Dec. 31, 2013	Mar. 31, 2013
Current assets:	'	'
Cash and cash equivalent	$16,949,616	$29,924,188
Accounts receivable	0	135,237
Prepaid accounts (NOTE 2)	354,208	20,972
Prepaid land lease - short term(NOTE 3)	328,036	'
Inventory(NOTE 4)	2,290,789	1,296,550
Total current assets	19,922,649	31,376,947
Prepaid land lease - long term(NOTE 3)	1,148,124	'
Development cost of acer truncatum bunge planting	14,003,182	'
Plant, property and equipment, net (NOTE 5)	13,765,156	9,409,916
Construction in progress(NOTE 6)	0	220,874
Intangible assets, net(NOTE 8)	17,145,456	17,656,561
Total assets	65,984,567	58,664,298
Current liabilities:	'	'
Tax payable(NOTE 9)	553,470	886,706
Other payable	8,401	366,818
Total current liabilities	561,871	1,253,524
Total liabilities	561,871	1,253,524
Stockholders' Equity(NOTE 12)	'	'
Preferred stock, par value $500.00 per share; 45 shares authorized and issued at September 30, 2013 and March 31, 2012	22,500	22,500
Common stock, par value $0.001 per share; 500,000,000 and 100,000,000 shares authorized, 29,663,023 shares issued and outstanding at September 30, 2013 and March 31, 2013, respectively	29,663	29,663
Additional paid-in capital	4,180,095	4,180,095
Statutory reserve	1,828,504	956,633
Retained earnings	54,113,338	48,426,955
Accumulated other comprehensive income	5,248,596	3,794,929
Total stockholders' equity	65,422,696	57,410,775
Total liabilities and stockholders' equity	$65,984,567	$58,664,298

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Preferred stock, par value (in dollars per share)	$500	$500
Preferred stock, shares authorized	45	45
Preferred stock, shares issued	45	45
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	100,000,000
Common stock, shares issued	29,663,023	29,663,023
Common stock, shares outstanding	29,663,023	29,663,023

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Sales Revenue	$8,276,400	$6,922,363	$24,633,947	$23,521,007
Cost of Goods Sold	3,639,944	3,450,065	11,314,805	11,367,854
Gross Profit	4,636,456	3,472,298	13,319,142	12,153,153
Selling Expenses	856,020	552,318	1,946,148	2,216,642
G&A Expense	894,674	1,184,227	2,026,062	2,387,125
R&D Expenses	60,634	723,790	708,158	1,272,490
Total expense	1,811,329	2,460,335	4,680,368	5,876,257
Income from operation	2,825,127	1,011,963	8,638,774	6,276,896
Interest income (Expense)	20,764	23,346	49,496	82,138
Unrealized gain on derivative(NOTE 11)	0	3,872,370	0	8,297,884
Profit before tax	2,845,891	4,907,679	8,688,270	14,656,918
Income tax(NOTE 10)	649,154	258,827	2,130,015	1,585,251
Net income	2,196,737	4,648,852	6,558,255	13,071,667
Other comprehensive income	'	'	'	'
Foreign currency translation adjustment	537,410	474,863	1,453,667	305,206
Comprehensive income	$2,734,147	$5,123,715	$8,011,922	$13,376,873
Basic and diluted income per common share	'	'	'	'
Basic and Diluted (in dollars per share)	$0.07	$0.11	$0.22	$0.22
Weighted average number of common shares outstanding	'	'	'	'
Basic and Diluted (in shares)	29,663,023	43,029,245	29,663,023	60,029,581

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Preferred Stock Series A	Common shares	Additional paid-in capital	Statutory Reserve	Accumulated OCI	Retained Earnings
Balance at Mar. 31, 2013	$57,410,775	$22,500	$29,663	$4,180,095	$956,633	$3,794,929	$48,426,955
Beginning Balance (in shares) at Mar. 31, 2013	'	45	29,663,023	'	'	'	'
Net income for the year	1,921,617	'	'	'	'	'	1,921,617
Other Comprehensive income, net of tax	0	'	'	'	'	'	'
Foreign currency translation adjustment	609,083	'	'	'	'	609,083	'
Balance at Jun. 30, 2013	59,941,475	22,500	29,663	4,180,095	956,633	4,404,012	50,348,572
Ending Balance (in shares) at Jun. 30, 2013	'	45	29,663,023	'	'	'	'
Net income for the year	2,439,900	'	'	'	'	'	2,439,900
Other Comprehensive income, net of tax	0	'	'	'	'	'	'
Foreign currency translation adjustment	307,174	'	'	'	'	307,174	'
Balance at Sep. 30, 2013	62,688,549	22,500	29,663	4,180,095	956,633	4,711,186	52,788,472
Ending Balance (in shares) at Sep. 30, 2013	'	45	29,663,023	'	'	'	'
Net income for the year	2,196,737	'	'	'	'	'	2,196,737
Statutory reserve	'	'	'	'	871,871	'	-871,871
Other Comprehensive income, net of tax	0	'	'	'	'	'	'
Foreign currency translation adjustment	537,410	'	'	'	'	537,410	'
Balance at Dec. 31, 2013	$65,422,696	$22,500	$29,663	$4,180,095	$1,828,504	$5,248,596	$54,113,338
Ending Balance (in shares) at Dec. 31, 2013	'	45	29,663,023	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW (USD $)	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities:	'	'
Net income	$6,558,255	$13,071,667
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	1,236,897	1,225,386
Issue of common shares as compensation	0	5,000
Common stock cancellation pursuant to the Termination Agreement	0	-2,765,993
Unrealized gain on derivative	0	-5,531,892
Changes in operating assets and liabilities:	'	'
Inventory	-994,239	-582,564
Prepaid land lease	-1,476,160	0
Accounts receivable	135,238	115,938
Taxes payable	-333,236	-593,671
Accrued expenses and other payables	-358,419	41,320
Net cash provided by (used in) operating activities	4,768,336	4,985,191
Cash flows from investing activities:	'	'
Addition to plant and equipment	-4,400,491	-73,502
Development cost of acer truncatum bunge planting	-14,003,182	0
Reduction of construction in progress	220,874	0
Net cash provided by (used in) investing activities	-18,182,799	-73,502
Effect of exchange rate changes on cash and cash equivalents	439,891	256,578
Net increase (decrease) in cash and cash equivalents	-12,974,572	5,168,267
Cash and cash equivalents at beginning of period	29,924,188	22,146,240
Cash and cash equivalents at ending of period	16,949,616	27,314,507
Cash paid during the periods for:	'	'
Interest	0	82,138
Income taxes	1,976,747	2,178,922
Non-cash financing activities:	'	'
Stock issued for services	'	50,000
Stock cancelled for return of patent	'	$44,255,087

BASIS_OF_PRESENTATION_AND_SIGN

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
	Nature of Operations
	China YCT International Group, Inc. (“China YCT”) was incorporated in the State of Florida, in the United States of America (the “USA”) in January 1989, and reincorporated in the State of Delaware on April 4, 2007.   China YCT, through its 100% owned subsidiary Landway Nano Bio-Tech, Inc. (“Landway Nano”), incorporated in Delaware, owns 100% of Shandong Spring Pharmaceutical Co., Ltd. (“Shandong Spring”), incorporated in the People’s Republic of China (“PRC”). China YCT International Group, Inc. and its subsidiaries are collectively referred to as the “Company”. Shandong Spring is engaged in the business of developing, manufacturing, and selling its own medicine made primarily from gingko extract, development of the acer truncatum bunge planting bases,and distributing health care supplement products manufactured by another company in the PRC.
	Unaudited Interim Financial Information
	The accompanying unaudited interim consolidated financial statements and information have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and in accordance with the instructions for Form 10-Q, and such financial statements and information do not include all of the information and disclosures required by US GAAP for complete financial statements. In the opinion of management, these financial statements contain all normal and recurring adjustments considered necessary to present fairly the financial position, results of operations, cash flows, and statement of stockholders’ equity for the periods presented. The results for the three and nine months ended December 31, 2013 are not necessarily indicative of the results to be expected for the full year.
	These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2013 filed with the Securities and Exchange Commission on July 1, 2013.
	Significant Accounting Polices
	Basis of presentation
	The consolidated financial statements of the Company are prepared in accordance with US GAAP.
	Principles of consolidation
	The consolidated financial statements include the financial statements of China YCT, and its subsidiaries, Shandong Spring and Landway Nano.  All inter-company transactions and balances are eliminated in consolidation.
	Use of estimates
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.
	Cash and cash equivalents
	For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
	Inventory
	Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of i) their costs or ii) market value with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.
	Property and equipment
	Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:
	Building		30-35 years
	Machinery, equipment and automobiles		7-15 years
	Furniture and fixtures		7-10 years
	Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.
	Intangible Assets
	(i)	Land Use Rights:
	All land in the PRC is owned by the government and cannot be sold to any individual or company.  However, the government may grant a “land use right” for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.
	(ii)	Patents:
	In March 2010, the Company purchased one patent from Shandong YCT Corp. that enables the Company to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.  The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.
	In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are “Treatment to ischemic encephalopathy and its preparation method” (ZL200510045001.9) and “Chinese herbal medicine compound to treat renal insufficiency and its preparation” (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.
	Development costs of acer truncatum bunge planting
	The Company has started development of the acer truncatum bunge planting bases and completed planting of 2,000Mu (1Mu is equal to approximately 666.67 square meters) as of the quarter ended December 31, 2013. The agricultural product (e.g., seeds, oil extract, etc.) derived from the planting is intended to be the supply for an integrated usage including edible oil, protein, medicine and health care, tannin extract, industrial chemicals, nectar source, nervonic acid, and specialty lumber, as well as for landscaping and conservation of soil and water.
	The Company accounts for the development costs of the planting in accordance to ASC Codification 905.  Pursuant toASC 905-360-25-3, limited-life land development costs and direct and indirect development costs of orchards, groves, vineyards, and intermediate-life plants shall be capitalized during the development period.  Pursuant toASC 905-360-35-7, costs capitalized during the development period under paragraph 905-360-25-3 shall be depreciated over the estimated useful life of the land development or that of the tree, vine, or plant. The planting is currently in the development stage with production expected in 2015; therefore, no depreciation expenses were recognized as of December 31, 2013.
	Revenue recognition
	The Company’s revenue recognition policies are in compliance with Staff Accounting Bulletin (“SAB”) 104, included in the Codification as ASC 605, Revenue Recognition. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.
	Unearned revenue
	Revenue from the sale of goods or services is recognized at the time that goods are delivered or services are rendered. Receipts in advance for goods to be delivered or services to be rendered in a subsequent period are carried forward as unearned revenue.
	Impairment of long-lived assets
	The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Pursuant to ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Pursuant to ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).
	Income taxes
	The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (”SFAS”) No. 109, “ Accounting for Income Taxes ”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2013 and March 31, 2013.
	The Company is a holding company Landway Nano, which is a holding company of Shandong Spring and does not have any operating activities.  Although the contract of the acquisition of the US patent was executed by the Company, in substance, the patent was acquired and is used by the Company’s operating entity in China.  For the same reason, the amortization of the patent was a deduction to the Chinese operating entity’s tax liability.  Therefore, the Company does not incur any US income tax liabilities for the acquisition of such patent.
	Value-added tax
	Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (“VAT”). All of the Company’s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.
	The Company recorded net VAT receivable in the amount of $101,985 and VAT Payable in the amount of $349,994 as of December 31, 2013 and March 31, 2013, respectively.
	Research and development
	Research and development costs relate to the Company’s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.
	The research and development expenses for the three months ended December 31, 2013 and 2012 were$60,634 and $723,790, respectively.
	The research and development expenses for the nine months ended December 31, 2013 and 2012 were$708,158 and $1,272,490, respectively.
	Advertising costs
	Advertising costs for newspaper and television are expensed as incurred in accordance to the ASC 720-35 “Advertising Costs”.  Pursuant to ASC 720-35-25-5, costs of communication advertising are not incurred until the item or service has been received and shall not be reported as expenses before the item or service has been received, except as discussed in paragraph 340-20-25-2.
	The Company incurred advertising costs of $321,669 and $158,750 for the three months ended December 31, 2013 and 2012, respectively.
	The Company incurred advertising costs of $321,669 and $759,866 for the nine months ended December 31, 2013 and 2012, respectively.
	Deferred advertising costs of $332,645 at quarter-end December 31, 2013 are classified as prepaid expenses on the balance sheet.
	Mailing and handling costs
	The Company accounts for mailing and handling fees in accordance with the FASB ASC 605-45 (Emerging Issues Task Force (EITF) Issue No.00-10,Accounting for Shipping and Handling Fees and Costs). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.
	For the three months ended December 31, 2013 and 2012, the Company incurred $296,892 and $218,820 mailing and handling costs, respectively.
	For the nine months ended December 31, 2013 and 2012, the Company incurred $914,478 and $765,413 mailing and handling costs, respectively.
	Stock Based Compensation
	The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.  The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.
	Net income (loss) per share (“EPS”)
	Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.
	There are nil common stock equivalents available for dilution purposes as of December 31, 2013 and 2012, respectively.
	Risks and uncertainties
The Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.
Fair Value of Financial Instruments
For certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.
As of December 31, 2013, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.
Foreign currency translation
The accounts of the Company’s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (“ASC”) Topic 830 “Foreign Currency Matters,” with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders’ equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, “Comprehensive Income.” Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.
Translation adjustments resulting from this process amounted to $5,248,596 and $3,794,929 as of December 31, 2013 and March 31, 2013, respectively.
The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:
		December 31,		March 31,		December 31,
		2013		2013		2012
Quarter End RMB Exchange Rate (RMB/USD$)			6.0969		6.2689		6.2855
Quarterly Average RMB Exchange Rate (RMB/USD$)			6.1302		6.2785		6.2992
Recent accounting pronouncements
The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these consolidated financial statements and does not believe that they will have a material effect on the Company’s consolidated financial position and results of operations.

PREPAID_ACCOUNTS

PREPAID ACCOUNTS	9 Months Ended
	Dec. 31, 2013
Prepaid Expenses and Other Current Assets Disclosure [Abstract]	'
PREPAID ACCOUNTS	'
	NOTE 2 – PREPAID ACCOUNTS
	The prepaid account in the amount of $354,208 as of December 31, 2013 includes a prepayment of $21,563 to Shandong YCT for purchase of its health products and deferred advertising costs of $332,645 for TV commercials.
	The prepaid account in the amount of $20,972 as of March 31, 2013 is a prepayment to Shandong YCT for purchase of its health products.

PREPAID_LAND_LEASE

PREPAID LAND LEASE	9 Months Ended
	Dec. 31, 2013
Prepaid Land Lease [Abstract]	'
PREPAID LAND LEASE	'
	NOTE 3 – PREPAID LAND LEASE
	The Company entered into a Farmland Leasing Agreement on June 20, 2013 for the lease of 2,000Mu farmland for the development of the acer truncatum bunge planting bases.  The lease term is from July 1, 2013 to June 30, 2043. The lease payment is about RMB1, 000(approximately USD 163) per Mu annually and payable for five years of rents in advance. The first lease payment was for the rents of the first five years in the amount of RMB10, 000,000 (approximately USD 1,626,545), whichweremade within 15 working days from the signing of the Lease.
	The Company accounts for the lease agreement as an operating lease in accordance to ASC 840-10-25-37, which requires, if land is the sole item of property leased and either the transfer-of-ownership criterion in paragraph 840-10-25-1(a) or the bargain-purchase-option criterion in paragraph 840-10-25-1(b) is met, the lessee shall account for the lease as a capital lease.  Otherwise, the lessee shall account for the lease as an operating lease.  Per ASC 840-2-25-1, rent shall be charged to expense by lessees over the lease term as it becomes payable.
	The components of prepaid land lease were as follows:
		As of
		December		March 31,
		31, 2013		2013
	Prepaid land lease – short term	$	328,036	$	-
	Prepaid land lease – long term		1,148,124		-
	Total prepaid land lease	$	1,476,160	$	-
	The prepaid land lease is amortized based on straight-line method.  The lease expenses for the three and nine months ended December 31, 2013 were$81,563 and $162,630, respectively.

INVENTORY

INVENTORY	9 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
INVENTORY	'
	NOTE 4 - INVENTORY
	Inventory consists of finished goods, work-in-process, and raw materials. No allowance for inventory was made for the three months and nine months ended December 31, 2013 and 2012. The components of inventories were as follows:
		As of
		December		March 31,
		31, 2013		2013
	Raw materials	$	1,197,950	$	864,956
	Work-in-progress		367,673		391,711
	Finished goods		725,166		39,883
	Total Inventories	$	2,290,789	$	1,296,550

PLANT_PROPERTY_AND_EQUIPMENT_N

PLANT, PROPERTY AND EQUIPMENT, NET	9 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PLANT, PROPERTY AND EQUIPMENT, NET	'
	NOTE 5 – PLANT, PROPERTY AND EQUIPMENT, NET
	The components of property and equipment were as follows:
		As of
		December		March 31,
		31, 2013		2013
	Machinery & Equipment	$	1,493,931	$	638,221
	Furniture & Fixture		169,863		165,203
	Building		13,979,899		10,150,522
	Subtotal		15,643,693		10,953,946
	Less: Accumulated Depreciation		-1,878,537		-1,544,030
	Total plant, property and equipment, net	$	13,765,156	$	9,409,916
	The depreciation expenses for the three months ended December 31, 2013 and 2012 were $334,508 and $84,813, respectively.
	The depreciation expenses for the nine months ended December 31, 2013 and 2012 were $675,465 and $261,143, respectively.

CONSTRUCTION_IN_PROGRESS

CONSTRUCTION IN PROGRESS	9 Months Ended
	Dec. 31, 2013
Construction In Progress Disclosure [Abstract]	'
CONSTRUCTION IN PROGRESS	'
	NOTE 6 – CONSTRUCTION IN PROGRESS
	Construction in progress represents direct costs of construction or acquisition and design fees incurred for the Company’s new plant and equipment. Capitalization of these costs ceases and the construction in progress is transferred to plant and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is made until construction is completed and put into use.

MAJOR_CUSTOMER_AND_VENDOR

MAJOR CUSTOMER AND VENDOR	9 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
MAJOR CUSTOMER AND VENDOR	'
	NOTE 7 - MAJOR CUSTOMER AND VENDOR
	In the three and nine months ended December 31, 2013, the Company mainly sold products to individual retail customers through nine major distributors.
	For the three months ended December 31, 2013, the purchase from four major vendors was $4,393,458 representing 91.1% of the Company’s total purchase for the quarter.
	For the nine months ended December 31, 2013, the purchase from four major vendors was $11,035,274, representing 89.7% of the Company’s total purchase for the period.

INTANGIBLE_ASSETS_NET

INTANGIBLE ASSETS, NET	9 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS, NET	'
	NOTE 8 - INTANGIBLE ASSETS, NET
	The intangible assets of the Company consist of land use right and purchased patents.
	Net land use right and purchased patents were as follows:
			As of
		Amortization	December		March 31, 2013
		Period	31, 2013
	Land use right	50 years		1,664,451	$	1,618,785
	Less: Accumulated amortization			-242,253		-211,149
	Land use right, net			1,422,199		1,407,636
	Patent 1	16.5 years		7,544,818		7,337,810
	Patent (non-US No. ZL200510045001.9)	13.75 years		9,984,927		9,890,092
	Patent (non-US No. ZL200710013301.8)	14.95 years		1,612,944		1,569,168
	Less: Accumulated amortization			-3,419,431		-2,548,146
	Patents, net		$	15,723,257	$	16,248,925
	The amortization expenses of land use right for the three months ended December 31, 2013 and 2012 were$10,326 and $9,831, respectively.  The amortization expenses of patents for the three months ended December 31, 2013 and 2012 were$353,717 and $330,933, respectively.
	The amortization expenses of land use right for the nine months ended December 31, 2013 and 2012 were$31,104 and $24,545, respectively.  The amortization expenses of patents for the nine months ended December 31, 2013 and 2012 were$871,285 and $939,698, respectively.

TAX_PAYABLE

TAX PAYABLE	9 Months Ended
	Dec. 31, 2013
Tax Disclosure [Abstract]	'
TAX PAYABLE	'
	NOTE 9 - TAX PAYABLE
	Tax payable at December 31, 2013 and March 31, 2013 were as follows:
		As of
		December 31, 2013		March 31, 2013
	Corporate Income Tax	$	652,700	$	508,024
	Value-Added Tax		-101,985		349,994
	Other Tax & Fees		2,756		28,688
	Total Tax Payable	$	553,470	$	886,706

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 10 - INCOME TAXES
	Shandong Spring Pharmaceutical Co., Ltd is subject to the Chinese Enterprise Income Tax (“EIT”) at a statutory rate of 25%.
	For the three months ended December 31, 2013 and 2012, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $649,154 and $258,827, respectively.
	For the nine months ended December 31, 2013 and 2012, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $2,130,015 and $1,585,251, respectively.

UNREALIZED_GAIN_ON_FAIR_VALUE_

UNREALIZED GAIN ON FAIR VALUE OF DERIVATIVE	9 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
UNREALIZED GAIN ON FAIR VALUE OF DERIVATIVE	'
	NOTE 11 – UNREALIZED GAIN ON FAIR VALUE OF DERIVATIVE
	Unrealized gain on derivatives reflects a non-cash adjustment for changes in fair value of the Company’s derivative liability associated with a Purchase Agreement, as amended, of an U.S. patent, No. 6,475,531 B1 titled “Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function”,between the Company and L.Y. Research Corp., a New Jersey corporation, on February 28, 2011.  The Company incurred unrealized gain on derivative liability of $3,872,370 and $8,297,884 for the three and nine months ended December 31, 2012.  The unrealized gain on derivative reflected reduced fair value of the derivative liabilities resulting from the decrease in the market value of the CYIG stock.
	On October 29, 2012, because the conditions set forthin the Purchase Agreement were not fulfilled, the Company and L.Y. Research Corp.entered into a Termination Agreement to formally terminate the Purchase Agreement, and the Patent was returned to L.Y. Research Corp.and the purchase payment, including the Company’s shares, was returned to the Company.  As a result, the derivative obligation and the unrealized gain were reversed by the carrying amount of $1,106,378 and $4,425,514, respectively.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 12 - STOCKHOLDERS’ EQUITY
	Stock Issued to Independent Directors
	The total amount of the compensation in the form of issuing shares of common stock to the independent directors was nil for the nine months ended December 31, 2013 and $5,000 for the year ended March 31, 2013.
	Stock Issued for Acquisition of Patent
	On February 28, 2011, the Company issued 44,254,952 shares of common stock, as a part of the consideration to acquire the U.S. patent, No. 6,475,531 B1 titled “Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function”, from L.Y. Research Corp.   The shares of the common stock were valued at the average closing market price on February 28, 2011, aggregating$32,748,665.
	On October 29, 2012, because the conditions set forth in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a Termination Agreement to formally terminate the Purchase Agreement, and the Patent was returned to L.Y. Research Corp.and the purchase payment, including the Company’s shares, was returned to the Company.
	Statutory Reserve
	Subsidiaries incorporated in China are required to make appropriations to reserve funds, based on after-tax net income determined in accordance with generally accepted accounting principles of the People’s Republic of China (“PRC GAAP”).  Effective on January 1, 2006, the Company is only required to contribute once to the statutory reserve inan amount equal to 10% of the net income after tax per annum, and any contributions are not to exceed 50% of the respective companies’ registered capital.
	The Company appropriated $871,871 to the statutory reserve based on its net income in 2013.  As of December 31, 2013, the Company has appropriated a total of $1,828,504 to the statutory reserve.

FUTURE_MINIMUM_LEASE_PAYMENTS

FUTURE MINIMUM LEASE PAYMENTS	9 Months Ended
	Dec. 31, 2013
Operating Leases, Future Minimum Payments Receivable [Abstract]	'
FUTURE MINIMUM LEASE PAYMENTS	'
	NOTE 13 – FUTURE MINIMUM LEASE PAYMENTS
	As of December 31, 2013, future minimum lease payments under the operating lease pursuant to the Farmland Leasing Agreement were as follows:
	Fiscal year ended March 31		Operating Leases
	2014		82,009
	2015		328,036
	2016		328,036
	2017		328,036
	2018		328,036
	2019 and thereafter		8,282,898
	Total minimum lease payments	$	9,677,049
	The lease payments for the first five years have been made within 15 working days from lease signing; and therefore, resulted in prepaid lease payments as of December 31, 2013 (refer to FN#3).  The actual future minimum lease payment, after deduction of the prepaid amount of $1,476,160, is $8,200,889.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 14 – SUBSEQUENT EVENTS
	There have been no subsequent events after December 31, 2013

BASIS_OF_PRESENTATION_AND_SIGN1

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation
	The consolidated financial statements of the Company are prepared in accordance with US GAAP.
Principles of consolidation	'
	Principles of consolidation
	The consolidated financial statements include the financial statements of China YCT, and its subsidiaries, Shandong Spring and Landway Nano.  All inter-company transactions and balances are eliminated in consolidation.
Use of estimates	'
	Use of estimates
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.
Cash and cash equivalents	'
	Cash and cash equivalents
	For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Inventory	'
	Inventory
	Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of i) their costs or ii) market value with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.
Property and equipment	'
	Property and equipment
	Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:
	Building		30-35 years
	Machinery, equipment and automobiles		7-15 years
	Furniture and fixtures		7-10 years
	Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.
Intangible Assets	'
	Intangible Assets
	(i)	Land Use Rights:
	All land in the PRC is owned by the government and cannot be sold to any individual or company.  However, the government may grant a “land use right” for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.
	(ii)	Patents:
	In March 2010, the Company purchased one patent from Shandong YCT Corp. that enables the Company to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.  The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.
	In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are “Treatment to ischemic encephalopathy and its preparation method” (ZL200510045001.9) and “Chinese herbal medicine compound to treat renal insufficiency and its preparation” (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.
Development costs of acer truncatum bunge planting	'
	Development costs of acer truncatum bunge planting
	The Company has started development of the acer truncatum bunge planting bases and completed planting of 2,000Mu (1Mu is equal to approximately 666.67 square meters) as of the quarter ended December 31, 2013. The agricultural product (e.g., seeds, oil extract, etc.) derived from the planting is intended to be the supply for an integrated usage including edible oil, protein, medicine and health care, tannin extract, industrial chemicals, nectar source, nervonic acid, and specialty lumber, as well as for landscaping and conservation of soil and water.
	The Company accounts for the development costs of the planting in accordance to ASC Codification 905.  Pursuant toASC 905-360-25-3, limited-life land development costs and direct and indirect development costs of orchards, groves, vineyards, and intermediate-life plants shall be capitalized during the development period.  Pursuant toASC 905-360-35-7, costs capitalized during the development period under paragraph 905-360-25-3 shall be depreciated over the estimated useful life of the land development or that of the tree, vine, or plant. The planting is currently in the development stage with production expected in 2015; therefore, no depreciation expenses were recognized as of December 31, 2013.
Revenue recognition	'
	Revenue recognition
	The Company’s revenue recognition policies are in compliance with Staff Accounting Bulletin (“SAB”) 104, included in the Codification as ASC 605, Revenue Recognition. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.
Unearned revenue	'
	Unearned revenue
	Revenue from the sale of goods or services is recognized at the time that goods are delivered or services are rendered. Receipts in advance for goods to be delivered or services to be rendered in a subsequent period are carried forward as unearned revenue.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Pursuant to ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Pursuant to ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).
Income taxes	'
	Income taxes
	The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (”SFAS”) No. 109, “ Accounting for Income Taxes ”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2013 and March 31, 2013.
	The Company is a holding company Landway Nano, which is a holding company of Shandong Spring and does not have any operating activities.  Although the contract of the acquisition of the US patent was executed by the Company, in substance, the patent was acquired and is used by the Company’s operating entity in China.  For the same reason, the amortization of the patent was a deduction to the Chinese operating entity’s tax liability.  Therefore, the Company does not incur any US income tax liabilities for the acquisition of such patent.
Value-added tax	'
	Value-added tax
	Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (“VAT”). All of the Company’s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.
	The Company recorded net VAT receivable in the amount of $101,985 and VAT Payable in the amount of $349,994 as of December 31, 2013 and March 31, 2013, respectively.
Research and development	'
	Research and development
	Research and development costs relate to the Company’s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.
	The research and development expenses for the three months ended December 31, 2013 and 2012 were$60,634 and $723,790, respectively.
	The research and development expenses for the nine months ended December 31, 2013 and 2012 were$708,158 and $1,272,490, respectively.
Advertising costs	'
	Advertising costs
	Advertising costs for newspaper and television are expensed as incurred in accordance to the ASC 720-35 “Advertising Costs”.  Pursuant to ASC 720-35-25-5, costs of communication advertising are not incurred until the item or service has been received and shall not be reported as expenses before the item or service has been received, except as discussed in paragraph 340-20-25-2.
	The Company incurred advertising costs of $321,669 and $158,750 for the three months ended December 31, 2013 and 2012, respectively.
	The Company incurred advertising costs of $321,669 and $759,866 for the nine months ended December 31, 2013 and 2012, respectively.
	Deferred advertising costs of $332,645 at quarter-end December 31, 2013 are classified as prepaid expenses on the balance sheet.
Mailing and handling costs	'
	Mailing and handling costs
	The Company accounts for mailing and handling fees in accordance with the FASB ASC 605-45 (Emerging Issues Task Force (EITF) Issue No.00-10,Accounting for Shipping and Handling Fees and Costs). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.
	For the three months ended December 31, 2013 and 2012, the Company incurred $296,892 and $218,820 mailing and handling costs, respectively.
	For the nine months ended December 31, 2013 and 2012, the Company incurred $914,478 and $765,413 mailing and handling costs, respectively.
Stock Based Compensation	'
	Stock Based Compensation
	The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.  The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.
Net income (loss) per share ("EPS")	'
	Net income (loss) per share (“EPS”)
	Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.
	There are nil common stock equivalents available for dilution purposes as of December 31, 2013 and 2012, respectively.
Risks and uncertainties	'
	Risks and uncertainties
	The Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	For certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.
	As of December 31, 2013, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.
Foreign currency translation	'
	Foreign currency translation
	The accounts of the Company’s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (“ASC”) Topic 830 “Foreign Currency Matters,” with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders’ equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, “Comprehensive Income.” Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.
	Translation adjustments resulting from this process amounted to $5,248,596 and $3,794,929 as of December 31, 2013 and March 31, 2013, respectively.
	The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:
			December 31,		March 31,		December 31,
			2013		2013		2012
	Quarter End RMB Exchange Rate (RMB/USD$)			6.0969		6.2689		6.2855
	Quarterly Average RMB Exchange Rate (RMB/USD$)			6.1302		6.2785		6.2992
Recent accounting pronouncements	'
	Recent accounting pronouncements
	The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these consolidated financial statements and does not believe that they will have a material effect on the Company’s consolidated financial position and results of operations.

BASIS_OF_PRESENTATION_AND_SIGN2

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Useful Lives of Property and Equipment	'
	Depreciation is calculated using the straight-like method over the following useful lives:
	Building	30-35 years
	Machinery, equipment and automobiles	7-15 years
	Furniture and fixtures	7-10 years
Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars	'
	The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:
		December 31,		March 31,		December 31,
		2013		2013		2012
	Quarter End RMB Exchange Rate (RMB/USD$)		6.0969		6.2689		6.2855
	Quarterly Average RMB Exchange Rate (RMB/USD$)		6.1302		6.2785		6.2992

PREPAID_LAND_LEASE_Tables

PREPAID LAND LEASE (Tables)	9 Months Ended
	Dec. 31, 2013
Prepaid Land Lease [Abstract]	'
Schedule of Prepaid Land Lease	'
	The components of prepaid land lease were as follows:
		As of
		December		March 31,
		31, 2013		2013
	Prepaid land lease – short term	$	328,036	$	-
	Prepaid land lease – long term		1,148,124		-
	Total prepaid land lease	$	1,476,160	$	-

INVENTORY_Tables

INVENTORY (Tables)	9 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	The components of inventories were as follows:
		As of
		December		March 31,
		31, 2013		2013
	Raw materials	$	1,197,950	$	864,956
	Work-in-progress		367,673		391,711
	Finished goods		725,166		39,883
	Total Inventories	$	2,290,789	$	1,296,550

PLANT_PROPERTY_AND_EQUIPMENT_N1

PLANT, PROPERTY AND EQUIPMENT, NET (Tables)	9 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Components of Property and Equipment	'
	The components of property and equipment were as follows:
		As of
		December		March 31,
		31, 2013		2013
	Machinery & Equipment	$	1,493,931	$	638,221
	Furniture & Fixture		169,863		165,203
	Building		13,979,899		10,150,522
	Subtotal		15,643,693		10,953,946
	Less: Accumulated Depreciation		-1,878,537		-1,544,030
	Total plant, property and equipment, net	$	13,765,156	$	9,409,916

INTANGIBLE_ASSETS_NET_Tables

INTANGIBLE ASSETS, NET (Tables)	9 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Net Land Use Right and Purchased Patent	'
	Net land use right and purchased patents were as follows:
			As of
		Amortization	December		March 31, 2013
		Period	31, 2013
	Land use right	50 years		1,664,451	$	1,618,785
	Less: Accumulated amortization			-242,253		-211,149
	Land use right, net			1,422,199		1,407,636
	Patent 1	16.5 years		7,544,818		7,337,810
	Patent (non-US No. ZL200510045001.9)	13.75 years		9,984,927		9,890,092
	Patent (non-US No. ZL200710013301.8)	14.95 years		1,612,944		1,569,168
	Less: Accumulated amortization			-3,419,431		-2,548,146
	Patents, net		$	15,723,257	$	16,248,925

TAX_PAYABLE_Tables

TAX PAYABLE (Tables)	9 Months Ended
	Dec. 31, 2013
Tax Disclosure [Abstract]	'
Tax Payable	'
	Tax payable at December 31, 2013 and March 31, 2013 were as follows:
		As of
		December 31, 2013		March 31, 2013
	Corporate Income Tax	$	652,700	$	508,024
	Value-Added Tax		-101,985		349,994
	Other Tax & Fees		2,756		28,688
	Total Tax Payable	$	553,470	$	886,706

FUTURE_MINIMUM_LEASE_PAYMENTS_

FUTURE MINIMUM LEASE PAYMENTS (Tables)	9 Months Ended
	Dec. 31, 2013
Operating Leases, Future Minimum Payments Receivable [Abstract]	'
Schedule of Future Minimum Lease Payments For Operating Lease	'
	As of December 31, 2013, future minimum lease payments under the operating lease pursuant to the Farmland Leasing Agreement were as follows:
	Fiscal year ended March 31		Operating Leases
	2014		82,009
	2015		328,036
	2016		328,036
	2017		328,036
	2018		328,036
	2019 and thereafter		8,282,898
	Total minimum lease payments	$	9,677,049

Useful_Lives_of_Property_and_E

Useful Lives of Property and Equipment (Detail)	9 Months Ended
	Dec. 31, 2013
Buildings | Minimum	'
Property, Plant and Equipment [Line Items]	'
Useful lives of property and equipment	'30 years
Buildings | Maximum	'
Property, Plant and Equipment [Line Items]	'
Useful lives of property and equipment	'35 years
Machinery, equipment and automobiles | Minimum	'
Property, Plant and Equipment [Line Items]	'
Useful lives of property and equipment	'7 years
Machinery, equipment and automobiles | Maximum	'
Property, Plant and Equipment [Line Items]	'
Useful lives of property and equipment	'15 years
Furniture and fixtures | Minimum	'
Property, Plant and Equipment [Line Items]	'
Useful lives of property and equipment	'7 years
Furniture and fixtures | Maximum	'
Property, Plant and Equipment [Line Items]	'
Useful lives of property and equipment	'10 years

Exchange_Rates_Adopted_to_Tran

Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars (Detail)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Foreign Currency Exchange Rate [Line Items]	'	'	'
Quarter End RMB Exchange Rate (RMB/USD$)	6.0969	6.2689	6.2855
Quarterly Average RMB Exchange Rate (RMB/USD$)	6.1302	6.2785	6.2992

BASIS_OF_PRESENTATION_AND_SIGN3

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Landway Nano Bio-Tech, Inc.

Shandong Spring Pharmaceutical Co., Ltd.

Patent 1

Patent 1

Patents (non-US No. ZL200510045001.9)

Patents (non-US No. ZL200710013301.8)

Land use rights

Shandong YCT

Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership in subsidiaries

'

'

'

'

'

100.00%

100.00%

'

'

'

'

'

Useful life of intangible assets

'

'

'

'

'

'

'

'16 years 6 months

'20 years

'13 years 9 months

'14 years 11 months 12 days

'50 years

Value-added tax rate

'

'

17.00%

'

'

'

'

'

'

'

'

'

Net VAT receivable

$101,985

'

$101,985

'

'

'

'

'

'

'

'

'

Net VAT payable

349,994

'

349,994

'

349,994

'

'

'

'

'

'

'

Research and development expense

60,634

723,790

708,158

1,272,490

'

'

'

'

'

'

'

'

Advertising costs

321,669

158,750

321,669

759,866

'

'

'

'

'

'

'

'

Deferred advertising costs

332,645

'

332,645

'

'

'

'

'

'

'

'

'

Mailing and handling costs

296,892

218,820

914,478

765,413

'

'

'

'

'

'

'

'

Foreign currency transaction and translation adjustment

$5,248,596

'

$5,248,596

'

$3,794,929

'

'

'

'

'

'

'

PREPAID_ACCOUNTS_Additional_In

PREPAID ACCOUNTS - Additional Information (Detail) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Prepaid Expenses [Line Items]	'	'
Prepaid accounts	$354,208	$20,972
Deferred Advertising Costs	332,645	'
Shandong YCT	'	'
Prepaid Expenses [Line Items]	'	'
Prepaid accounts	21,563	20,972
TV Commercials [Member]	'	'
Prepaid Expenses [Line Items]	'	'
Deferred Advertising Costs	$332,645	'

PREPAID_LAND_LEASE_Detail

PREPAID LAND LEASE - (Detail) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Prepaid land lease - short term	$328,036	'
Prepaid land lease - long term	1,148,124	'
Total prepaid land lease	$1,476,160	$0

PREPAID_LAND_LEASE_Additional_

PREPAID LAND LEASE - Additional Information (Detail)	3 Months Ended	9 Months Ended	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Jun. 20, 2013	Jun. 20, 2013
	USD ($)	USD ($)	Farmland Leasing Agreement [Member]	Farmland Leasing Agreement [Member]
			USD ($)	CNY
Lease Term	'	'	'30 years	'30 years
Annual Operating Leases Rent Expense Minimum Rentals per Mu	'	'	$163	1,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months	'	'	1,626,545	10,000,000
Operating Leases, Rent Expense	$81,563	$162,630	'	'
Lease Payment Date of First Required Payment	'	'15 days	'15 days	'15 days

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Inventory Disclosure [Line Items]	'	'
Raw materials	$1,197,950	$864,956
Work-in-progress	367,673	391,711
Finished goods	725,166	39,883
Total Inventories	$2,290,789	$1,296,550

Components_of_Property_and_Equ

Components of Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Machinery & Equipment	$1,493,931	$638,221
Furniture & Fixture	169,863	165,203
Building	13,979,899	10,150,522
Subtotal	15,643,693	10,953,946
Less: Accumulated Depreciation	-1,878,537	-1,544,030
Total plant, property and equipment, net	$13,765,156	$9,409,916

PLANT_PROPERTY_AND_EQUIPMENT_N2

PLANT, PROPERTY AND EQUIPMENT, NET - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation expense	$334,508	$84,813	$675,465	$261,143

MAJOR_CUSTOMER_AND_VENDOR_Addi

MAJOR CUSTOMER AND VENDOR - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
Concentration Risk [Line Items]	'	'
Number of major distributors	9	9
Number of major vendors	4	4
Purchases from major suppliers	$4,393,458	$11,035,274
Percentage of purchases from major suppliers	91.10%	89.70%

Net_Land_Use_Right_and_Purchas

Net Land Use Right and Purchased Patent (Detail) (USD $)	9 Months Ended
	Dec. 31, 2013	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Less: Accumulated amortization	($3,419,431)	($2,548,146)
Intangible assets, net	17,145,456	17,656,561
Land use rights	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period	'50 years	'
Intangible assets, gross	1,664,451	1,618,785
Less: Accumulated amortization	-242,253	-211,149
Intangible assets, net	1,422,199	1,407,636
Patent 1	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period	'16 years 6 months	'
Intangible assets, gross	7,544,818	7,337,810
Patents (non-US No. ZL200510045001.9)	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period	'13 years 9 months	'
Intangible assets, gross	9,984,927	9,890,092
Patents (non-US No. ZL200710013301.8)	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period	'14 years 11 months 12 days	'
Intangible assets, gross	$1,612,944	$1,569,168

INTANGIBLE_ASSETS_NET_Addition

INTANGIBLE ASSETS, NET - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Land use rights	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense	$10,326	$9,831	$31,104	$24,545
Patents	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense	$353,717	$330,933	$871,285	$939,698

Tax_Payable_Detail

Tax Payable (Detail) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Taxes [Line Items]	'	'
Corporate Income Tax	$652,700	$508,024
Value-Added Tax	-101,985	349,994
Other Tax & Fees	2,756	28,688
Total Tax Payable	$553,470	$886,706

INCOME_TAXES_Additional_Inform

INCOME TAXES - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'	'	'
Income tax provisions	$649,154	$258,827	$2,130,015	$1,585,251
Shandong Spring Pharmaceutical	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Income tax at statutory rate	'	'	25.00%	'
Income tax provisions	$649,154	$258,827	$2,130,015	$1,585,251

UNREALIZED_GAIN_ON_FAIR_VALUE_1

UNREALIZED GAIN ON FAIR VALUE OF DERIVATIVE- Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Oct. 29, 2012
					L.Y. Research Corp [Member]
Fair Value of Financial Instruments [Line Items]	'	'	'	'	'
Unrealized Gain (Loss) on Derivatives	$0	$3,872,370	$0	$8,297,884	$4,425,514
Derivative Liability	'	'	'	'	$1,106,378

STOCKHOLDERS_EQUITY_Additional

STOCKHOLDERS' EQUITY - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended		1 Months Ended	9 Months Ended	12 Months Ended
	Jan. 01, 2006	Dec. 31, 2013	Mar. 31, 2013	Feb. 28, 2011	Dec. 31, 2013	Mar. 31, 2013
				Patent (U.S. No. 6,475,531 B1)	Independent Directors	Independent Directors
				L.Y. Research Corp [Member]
Class of Stock [Line Items]	'	'	'	'	'	'
Issuance of common shares to independent directors, value	'	'	'	'	$0	$5,000
Statutory reserve fund	10.00%	'	'	'	'	'
Statutory reserve fund	50.00%	'	'	'	'	'
Statutory reserve on its net income	'	871,871	'	'	'	'
Statutory reserve	'	1,828,504	956,633	'	'	'
Stock Issued During Period, Shares, Purchase of Assets	'	'	'	44,254,952	'	'
Stock Issued During Period, Value, Purchase of Assets	'	'	'	$32,748,665	'	'

FUTURE_MINIMUM_LEASE_PAYMENTS_1

FUTURE MINIMUM LEASE PAYMENTS - (Detail) (USD $)	Dec. 31, 2013
Operating Leased Assets [Line Items]	'
2014	$82,009
2015	328,036
2016	328,036
2017	328,036
2018	328,036
2019 and thereafter	8,282,898
Total minimum lease payments	$9,677,049

FUTURE_MINIMUM_LEASE_PAYMENTS_2

FUTURE MINIMUM LEASE PAYMENTS -Additional Information (Detail) (USD $)	9 Months Ended
	Dec. 31, 2013
Operating Leased Assets [Line Items]	'
Prepaid Amount Of Future Minimum Lease Payment	$1,476,160
Operating Leases, Future Minimum Payments, Due Thereafter	$8,200,889
Lease Payment Date of First Required Payment	'15 days